CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
- This study is being done to find out if extending adjuvant chemotherapy for patients by
giving additional chemotherapy can lengthen the amount of time before their cancer comes
back. The additional chemotherapy is called capecitabine.
- Capecitabine is an oral drug (taken by mouth). It is approved by the US Food and Drug
Administration (FDA) for adjuvant treatment of adults with pancreatic cancer and also
for the treatment of other types of cancer